(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.79%) $83.19
(-1.16%) $1.619
(-0.39%) $2 338.10
(1.06%) $27.54
(0.67%) $928.30
(-0.19%) $0.933
(-0.12%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer...
Stats | |
---|---|
Šios dienos apimtis | 1.78M |
Vidutinė apimtis | 1.24M |
Rinkos kapitalizacija | 127.96M |
EPS | $-53.13 ( 2023-09-29 ) |
Last Dividend | $0.360 ( 2023-03-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.29 |
ATR14 | $0.0360 (5.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-06 | Kelly Steven | Buy | 600 000 | Stock Option (Right to Buy) |
2023-06-06 | Zweifach Sanford S | Buy | 38 700 | Stock Option (Right to Buy) |
2023-06-06 | Morris Richard Steven | Buy | 238 000 | Stock Option (Right to Buy) |
2023-06-06 | Torok Michael | Buy | 38 700 | Stock Option (Right to Buy) |
2023-06-06 | Klichinsky Michael | Buy | 238 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
76.64 |
Last 87 transactions |
Buy: 18 644 112 | Sell: 1 508 721 |
Tūris Koreliacija
Sesen Bio Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BOCH | 0.945 |
SHSP | 0.905 |
DYNT | 0.846 |
SGC | 0.836 |
MMAC | 0.83 |
WWD | 0.829 |
SYKE | 0.826 |
LIVE | 0.825 |
DGLY | 0.823 |
ECOR | 0.817 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
GAINL | -0.898 |
APOP | -0.887 |
TDAC | -0.884 |
RMRM | -0.88 |
ISNS | -0.872 |
SVOK | -0.829 |
VERA | -0.822 |
AHPI | -0.801 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sesen Bio Inc Koreliacija - Valiuta/Žaliavos
Sesen Bio Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $40.00M |
Bruto pelnas: | $40.00M (100.00 %) |
EPS: | $-1.990 |
FY | 2022 |
Pajamos: | $40.00M |
Bruto pelnas: | $40.00M (100.00 %) |
EPS: | $-1.990 |
FY | 2021 |
Pajamos: | $26.54M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.00184 |
FY | 2020 |
Pajamos: | $11.24M |
Bruto pelnas: | $11.24 (0.00 %) |
EPS: | $-0.190 |
Financial Reports:
No articles found.
Sesen Bio Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.360 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.360 | 2023-03-06 |
Last Dividend | $0.360 | 2023-03-06 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.360 | -- |
Avg. Dividend % Per Year | 18.77% | -- |
Score | 4.82 | -- |
Div. Sustainability Score | 5.13 | |
Div.Growth Potential Score | 0.276 | |
Div. Directional Score | 2.70 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.360 | 56.30% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.605 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.761 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.910 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.53 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.27 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.42 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0257 | -1.500 | 9.57 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 11.34 | 1.000 | 6.91 | 6.91 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0199 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0166 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0593 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.510 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.292 | 1.000 | 9.49 | 9.49 | [0.2 - 2] |
assetTurnoverTTM | 0.474 | 0.800 | -0.172 | -0.138 | [0.5 - 2] |
Total Score | 5.13 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.312 | 1.000 | -0.133 | 0 | [1 - 100] |
returnOnEquityTTM | -0.910 | 2.50 | -7.21 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0166 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0199 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0158 | 1.000 | -2.10 | 0 | [0.1 - 0.5] |
Total Score | 0.276 |
Sesen Bio Inc
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.